Physicochemical Properties
| Molecular Formula | C24H22F2N2O2 |
| Molecular Weight | 408.4405 |
| Exact Mass | 408.164 |
| CAS # | 1346133-11-6 |
| PubChem CID | 56655502 |
| Appearance | Light yellow to yellow solid powder |
| LogP | 4.4 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 5 |
| Rotatable Bond Count | 6 |
| Heavy Atom Count | 30 |
| Complexity | 569 |
| Defined Atom Stereocenter Count | 1 |
| SMILES | FC1=C([H])C([H])=C([H])C(=C1[H])[C@]1([H])C([H])([H])C([H])([H])C([H])([H])N1C([H])([H])C1C([H])=C([H])C(=C([H])C=1[H])OC1C([H])=C([H])C(C(N([H])[H])=O)=C([H])C=1F |
| InChi Key | WHHMECUDUQRPJT-QFIPXVFZSA-N |
| InChi Code | InChI=1S/C24H22F2N2O2/c25-19-4-1-3-17(13-19)22-5-2-12-28(22)15-16-6-9-20(10-7-16)30-23-11-8-18(24(27)29)14-21(23)26/h1,3-4,6-11,13-14,22H,2,5,12,15H2,(H2,27,29)/t22-/m0/s1 |
| Chemical Name | 3-fluoro-4-[4-[[(2S)-2-(3-fluorophenyl)pyrrolidin-1-yl]methyl]phenoxy]benzamide |
| Synonyms | LY2444296; LY-2444296 |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| ln Vivo | LY2444296 showed anxiolytic-like effects in the EPM test [1]. LY2444296 (3 mg/kg; i.p.; 30 minutes before U69,593 administration) inhibits behavioral and neuroendocrine effects caused by the reference kappa agonist U69,593 in cocaine-naïve rats [2]. LY2444296 lowers anxiety-like and depressive-like behaviors and CORT release in rats assessed following chronic self-administration of cocaine, but not in cocaine-naïve rats [2] |
| Animal Protocol |
Animal/Disease Models: Adult male SD (SD (Sprague-Dawley)) rat (240–250 g) [2] Doses: 3 mg/kg Route of Administration: intraperitoneal (ip) injection; 30 minutes before administration of U69,593 Experimental Results: Prevention of U69,593 effects on the untreated Behavioral and neuroendocrine effects in rats exposed to cocaine. |
| References |
[1]. Two short-acting kappa opioid receptor antagonists (zyklophin and LY2444296) exhibited different behavioral effects from the long-acting antagonist norbinaltorphimine in mouse anxiety tests. Neurosci Lett. 2016 Feb 26;615:15-20. [2]. "Effects of the novel relatively short-acting kappa opioid receptor antagonist LY2444296 in behaviors observed after chronic extended-access cocaine self-administration in rats". Psychopharmacology (Berl). 2017 Aug;234(15):2219-2231. |
Solubility Data
| Solubility (In Vitro) | Ethanol : ~27.5 mg/mL (~67.33 mM) |
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.75 mg/mL (6.73 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: ≥ 2.75 mg/mL (6.73 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 27.5 mg/mL clear EtOH stock solution to 900 μL of corn oil and mix well. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4483 mL | 12.2417 mL | 24.4834 mL | |
| 5 mM | 0.4897 mL | 2.4483 mL | 4.8967 mL | |
| 10 mM | 0.2448 mL | 1.2242 mL | 2.4483 mL |